Bristol-Myers Squibb Co. (BMY)

Statement of Financial Position, Liabilities and Stockholders' Equity

Difficulty: Beginner

Annual Data

Quarterly Data

The statement of financial position provides creditors, investors, and analysts with information on company's resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company's assets as well as an indication of cash flows that may come from receivables and inventories.

Liabilities represents obligations of a company arising from past events, the settlement of which is expected to result in an outflow of economic benefits from the entity.

Bristol-Myers Squibb Co., Consolidated Statement of Financial Position, Liabilities and Stockholders' Equity

USD $ in millions

	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013
Short-term debt obligations	987	992	139	590	359
Accounts payable	2,248	1,664	1,565	2,487	2,559
Accrued rebates and returns	2,024	1,680	1,324	851	889
Employee compensation and benefits	869	818	904	892	735
Research and development	783	718	553	445	380
Dividends	654	660	655	645	634
Royalties	285	246	161	213	173
Branded Prescription Drug Fee	303	234	112	–	–
Restructuring	155	90	89	128	73
Pension and postretirement benefits	40	44	47	47	47
Litigation and other settlements	38	43	189	43	65
Other	863	738	704	691	679
Accrued liabilities	6,014	5,271	4,738	3,955	3,675
Deferred income	83	762	1,003	1,167	756
Income taxes payable	231	152	572	262	160
Liabilities related to assets held-for-sale	–	–	–	–	4,931
Current liabilities	9,563	8,841	8,017	8,461	12,440
Deferred income	454	547	586	770	769
Income taxes payable	3,548	973	742	560	823
Pension and other liabilities	1,164	1,283	1,429	1,733	1,343
Long-term debt, excluding current portion	6,975	5,716	6,550	7,242	7,981
Non-current liabilities	12,141	8,519	9,307	10,305	10,916
Total liabilities	21,704	17,360	17,324	18,766	23,356
Preferred stock, $2 convertible series, par value $1 per share	–	–	–	–	–
Common stock, par value of $0.10 per share	221	221	221	221	221
Capital in excess of par value of stock	1,898	1,725	1,459	1,507	1,922
Accumulated other comprehensive loss	(2,289)	(2,503)	(2,468)	(2,425)	(2,141)
Retained earnings	31,160	33,513	31,613	32,541	32,952
Cost of treasury stock	(19,249)	(16,779)	(16,559)	(16,992)	(17,800)
Total Bristol-Myers Squibb Company shareholders' equity	11,741	16,177	14,266	14,852	15,154
Noncontrolling interest	106	170	158	131	82
Total equity	11,847	16,347	14,424	14,983	15,236
Total liabilities and equity	33,551	33,707	31,748	33,749	38,592

Based on: 10-K (filing date: 2018-02-13), 10-K (filing date: 2017-02-21), 10-K (filing date: 2016-02-12), 10-K (filing date: 2015-02-13), 10-K (filing date: 2014-02-14).

Item	Description	The company
Current liabilities	Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.	Bristol-Myers Squibb Co.'s current liabilities increased from 2015 to 2016 and from 2016 to 2017.
Non-current liabilities	Amount of obligation due after one year or beyond the normal operating cycle, if longer.	Bristol-Myers Squibb Co.'s non-current liabilities declined from 2015 to 2016 but then increased from 2016 to 2017 exceeding 2015 level.
Total liabilities	Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.	Bristol-Myers Squibb Co.'s total liabilities increased from 2015 to 2016 and from 2016 to 2017.
Total Bristol-Myers Squibb Company shareholders' equity	Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.	Bristol-Myers Squibb Co.'s total Bristol-Myers Squibb Company shareholders' equity increased from 2015 to 2016 but then declined significantly from 2016 to 2017.